You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePimozide
Accession NumberDB01100  (APRD00218)
TypeSmall Molecule
GroupsApproved
DescriptionA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
Structure
Thumb
Synonyms
Halomonth
Neoperidole
Opiran
Orap
Pimozida
Pimozide
Pimozidum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Oraptablet1 mg/1oralTeva Select Brands2000-06-07Not applicableUs
Oraptablet4 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Oraptablet2 mg/1oralTeva Select Brands1990-09-30Not applicableUs
Oraptablet2 mg/1oralTeva Select Brands2014-10-31Not applicableUs
Oraptablet2 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Orap Tab 10mgtablet10 mgoralMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1983-12-311996-08-19Canada
Pimozidetablet2 mgoralAa Pharma Inc2003-04-01Not applicableCanada
Pimozidetablet4 mgoralAa Pharma Inc2003-04-01Not applicableCanada
PMS-pimozidetablet2 mgoralPharmascience Inc2002-10-18Not applicableCanada
PMS-pimozidetablet10 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-pimozidetablet4 mgoralPharmascience Inc2002-10-18Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pimozidetablet1 mg/1oralPar Pharmaceutical Inc.2014-12-01Not applicableUs
Pimozidetablet2 mg/1oralPar Pharmaceutical Inc.2014-12-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NeoperidoleNot Available
OpiranNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1HIZ4DL86F
CAS number2062-78-4
WeightAverage: 461.5462
Monoisotopic: 461.227868975
Chemical FormulaC28H29F2N3O
InChI KeyInChIKey=YVUQSNJEYSNKRX-UHFFFAOYSA-N
InChI
InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)
IUPAC Name
1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one
SMILES
FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylbutylamine
  • Benzimidazole
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • 4-aminopiperidine
  • Piperidine
  • N-substituted imidazole
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Urea
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
PharmacodynamicsPimozide is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide's therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized. Pimozide also has less potential for inducing sedation and hypotension as it has more specific dopamine receptor blocking activity than other neuroleptic agents (and is therefore a suitable alternative to haloperidol).
Mechanism of actionThe ability of pimozide to suppress motor and phonic tics in Tourette's Disorder is thought to be primarily a function of its dopaminergic blocking activity. Pimozide binds and inhibits the dopamine D2 receptor in the CNS.
Related Articles
AbsorptionGreater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Notable first-pass metabolism in the liver, primarily by N-dealkylation via the cytochrome P450 isoenzymes CYP3A and CYP1A2 (and possibly CYP2D6). The activity of the two major metabolites has not been determined.

Route of eliminationNot Available
Half life29 ± 10 hours (single-dose study of healthy volunteers).
ClearanceNot Available
ToxicityLD50 = 1100 mg/kg (rat, oral), 228 mg/kg (mouse, oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9685
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.6639
P-glycoprotein inhibitor IInhibitor0.8842
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.7255
CYP450 2C9 substrateNon-substrate0.7829
CYP450 2D6 substrateNon-substrate0.9112
CYP450 3A4 substrateSubstrate0.6579
CYP450 1A2 substrateInhibitor0.9062
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.686
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9217
Ames testNon AMES toxic0.7856
CarcinogenicityNon-carcinogens0.9348
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6925
hERG inhibition (predictor II)Inhibitor0.9192
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg/1
Tabletoral2 mg
Tabletoral2 mg/1
Tabletoral4 mg
Tabletoral10 mg
Prices
Unit descriptionCostUnit
Orap 1 mg tablet1.22USD tablet
Orap 2 mg tablet1.17USD tablet
Orap 4 mg Tablet0.47USD tablet
Apo-Pimozide 4 mg Tablet0.43USD tablet
Apo-Pimozide 2 mg Tablet0.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point214-218 °CPhysProp
water solubility10 mg/L (at 25 °C)MERCK INDEX (1996)
logP6.30HANSCH,C ET AL. (1995)
pKa8.63EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00173 mg/mLALOGPS
logP6.36ALOGPS
logP5.83ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)12.9ChemAxon
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.58 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity132.21 m3·mol-1ChemAxon
Polarizability50.04 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-4890100000-ff909df45204eac82c46View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AG02
AHFS Codes
  • 28:16.08.92
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (29 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Pimozide can be increased when it is combined with 1,10-Phenanthroline.
2-HYDROXY-1,4-NAPHTHOQUINONE2-HYDROXY-1,4-NAPHTHOQUINONE may increase the arrhythmogenic activities of Pimozide.
2-mercaptobenzothiazole2-mercaptobenzothiazole may increase the arrhythmogenic activities of Pimozide.
3,4-DichloroisocoumarinThe serum concentration of Pimozide can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetaminePimozide may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetaminePimozide may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Pimozide can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pimozide is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Pimozide can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Pimozide.
AcepromazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Pimozide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Pimozide.
adipiplonThe risk or severity of adverse effects can be increased when Pimozide is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Pimozide.
AgomelatineThe risk or severity of adverse effects can be increased when Pimozide is combined with Agomelatine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Pimozide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pimozide.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pimozide.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Pimozide.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pimozide.
AlogliptinThe serum concentration of Pimozide can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Pimozide can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pimozide is combined with Alphacetylmethadol.
AlprazolamThe serum concentration of Pimozide can be increased when it is combined with Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Pimozide is combined with Alprazolam.
AmantadineAmantadine may increase the QTc-prolonging activities of Pimozide.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Pimozide.
AmiodaroneThe serum concentration of Pimozide can be increased when it is combined with Amiodarone.
AmiodaronePimozide may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pimozide.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Pimozide.
AmlodipineThe serum concentration of Pimozide can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Amobarbital.
AmorolfineAmorolfine may increase the arrhythmogenic activities of Pimozide.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pimozide.
AmperozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amperozide.
AmphetaminePimozide may decrease the stimulatory activities of Amphetamine.
Amphotericin BAmphotericin B may increase the arrhythmogenic activities of Pimozide.
AmprenavirThe serum concentration of Pimozide can be increased when it is combined with Amprenavir.
AN2690AN2690 may increase the arrhythmogenic activities of Pimozide.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Pimozide.
AnidulafunginAnidulafungin may increase the arrhythmogenic activities of Pimozide.
Antithrombin III humanThe serum concentration of Pimozide can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Pimozide can be increased when it is combined with Apixaban.
ApomorphineApomorphine may increase the QTc-prolonging activities of Pimozide.
AprepitantThe serum concentration of Pimozide can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Pimozide can be increased when it is combined with Aprotinin.
ArformoterolArformoterol may increase the QTc-prolonging activities of Pimozide.
ArgatrobanThe serum concentration of Pimozide can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Pimozide is combined with Aripiprazole.
Arsenic trioxidePimozide may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherArtemether may increase the arrhythmogenic activities of Pimozide.
ArtemetherPimozide may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Articaine.
AsenapinePimozide may increase the QTc-prolonging activities of Asenapine.
AsunaprevirThe serum concentration of Pimozide can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Pimozide can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Pimozide.
AtomoxetineThe serum concentration of Pimozide can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Pimozide can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Pimozide.
AzaperoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Azaperone.
AzelastinePimozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pimozide.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Pimozide.
BaclofenThe risk or severity of adverse effects can be increased when Pimozide is combined with Baclofen.
Bafilomycin A1Bafilomycin A1 may increase the arrhythmogenic activities of Pimozide.
BarbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Barbital.
BatimastatThe serum concentration of Pimozide can be increased when it is combined with Batimastat.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Pimozide.
BenazeprilThe serum concentration of Pimozide can be increased when it is combined with Benazepril.
BenzamidineThe serum concentration of Pimozide can be increased when it is combined with Benzamidine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pimozide.
Benzoic AcidBenzoic Acid may increase the arrhythmogenic activities of Pimozide.
BenzphetaminePimozide may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pimozide is combined with Benzyl alcohol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Pimozide.
BexaroteneThe serum concentration of Pimozide can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Pimozide can be increased when it is combined with Bicalutamide.
BifonazoleBifonazole may increase the arrhythmogenic activities of Pimozide.
BivalirudinThe serum concentration of Pimozide can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Pimozide can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Pimozide can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Pimozide can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Pimozide.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Pimozide.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pimozide is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
BrimonidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pimozide.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Pimozide.
BrompheniramineThe risk or severity of adverse effects can be increased when Pimozide is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Pimozide is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pimozide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pimozide.
BupropionThe serum concentration of Pimozide can be increased when it is combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Pimozide.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pimozide.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pimozide.
ButacaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Pimozide is combined with Butamben.
ButenafineButenafine may increase the arrhythmogenic activities of Pimozide.
ButethalThe risk or severity of adverse effects can be increased when Pimozide is combined with Butethal.
ButoconazoleButoconazole may increase the arrhythmogenic activities of Pimozide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pimozide.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Pimozide.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Pimozide.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Pimozide.
CaffeineThe metabolism of Pimozide can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Pimozide.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Pimozide.
CandicidinCandicidin may increase the arrhythmogenic activities of Pimozide.
CandoxatrilThe serum concentration of Pimozide can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Pimozide can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Pimozide.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pimozide.
CarbinoxamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Pimozide is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Pimozide.
CarisoprodolThe risk or severity of adverse effects can be increased when Pimozide is combined with Carisoprodol.
CaspofunginCaspofungin may increase the arrhythmogenic activities of Pimozide.
CeritinibThe serum concentration of Pimozide can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Pimozide.
CeruleninCerulenin may increase the arrhythmogenic activities of Pimozide.
CetirizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Pimozide is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pimozide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Chloroprocaine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Pimozide.
ChloroxineChloroxine may increase the arrhythmogenic activities of Pimozide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorphenamine.
ChlorphenterminePimozide may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Pimozide.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Pimozide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorzoxazone.
ChymostatinThe serum concentration of Pimozide can be increased when it is combined with Chymostatin.
CiclopiroxCiclopirox may increase the arrhythmogenic activities of Pimozide.
CilastatinThe serum concentration of Pimozide can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Pimozide can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Pimozide can be increased when it is combined with Cilostazol.
CimetidineThe serum concentration of Pimozide can be increased when it is combined with Cimetidine.
CinacalcetThe serum concentration of Pimozide can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pimozide.
CiprofloxacinThe serum concentration of Pimozide can be increased when it is combined with Ciprofloxacin.
CisaprideCisapride may increase the QTc-prolonging activities of Pimozide.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Pimozide.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Pimozide.
CitalopramPimozide may increase the QTc-prolonging activities of Citalopram.
ClarithromycinThe serum concentration of Pimozide can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Pimozide can be increased when it is combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Pimozide is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Pimozide is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Pimozide.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Pimozide.
clomethiazoleThe risk or severity of adverse effects can be increased when Pimozide is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Pimozide.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pimozide.
ClonazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Pimozide.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pimozide.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Pimozide.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pimozide.
ClotrimazoleThe serum concentration of Pimozide can be increased when it is combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Pimozide.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Pimozide.
CobicistatThe serum concentration of Pimozide can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Pimozide.
CocaineThe serum concentration of Pimozide can be increased when it is combined with Cocaine.
CocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pimozide.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Pimozide.
ConivaptanThe serum concentration of Pimozide can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pimozide.
CrizotinibThe serum concentration of Pimozide can be increased when it is combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pimozide.
CyclosporineThe serum concentration of Pimozide can be increased when it is combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Pimozide can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Pimozide can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Pimozide can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Pimozide.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Pimozide.
DalfopristinThe serum concentration of Pimozide can be increased when it is combined with Dalfopristin.
DanazolThe serum concentration of Pimozide can be increased when it is combined with Danazol.
DantroleneThe risk or severity of adverse effects can be increased when Pimozide is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Pimozide.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pimozide.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pimozide.
DarunavirThe serum concentration of Pimozide can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Pimozide can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Pimozide.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Pimozide.
Decanoic AcidDecanoic Acid may increase the arrhythmogenic activities of Pimozide.
DeferasiroxThe serum concentration of Pimozide can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Pimozide.
DelavirdineThe serum concentration of Pimozide can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Pimozide is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Pimozide is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Pimozide.
DesloratadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Pimozide.
DetomidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Detomidine.
DexamethasoneThe serum concentration of Pimozide can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Pimozide.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pimozide.
DextroamphetaminePimozide may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pimozide.
DextromoramideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pimozide.
DezocineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Pimozide.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pimozide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Pimozide.
DifenoxinThe risk or severity of adverse effects can be increased when Pimozide is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Pimozide.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pimozide.
DihydrocodeineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydrocodeine.
DihydroergotamineThe serum concentration of Pimozide can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Pimozide.
DiltiazemThe serum concentration of Pimozide can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Pimozide is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pimozide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pimozide.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Pimozide.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Pimozide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Pimozide.
DofetilideDofetilide may increase the QTc-prolonging activities of Pimozide.
DolasetronDolasetron may increase the QTc-prolonging activities of Pimozide.
DomperidonePimozide may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Pimozide is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Pimozide.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Pimozide.
DoxycyclineThe serum concentration of Pimozide can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
DoxylamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Pimozide is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
DronedaroneThe serum concentration of Pimozide can be increased when it is combined with Dronedarone.
DronedaronePimozide may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Pimozide.
DroperidolThe risk or severity of adverse effects can be increased when Pimozide is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Pimozide is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pimozide.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pimozide.
EcabetThe serum concentration of Pimozide can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Pimozide is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Pimozide is combined with ECGONINE METHYL ESTER.
EconazoleEconazole may increase the arrhythmogenic activities of Pimozide.
EdoxabanThe serum concentration of Pimozide can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Pimozide can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Pimozide is combined with Efavirenz.
EfinaconazoleEfinaconazole may increase the arrhythmogenic activities of Pimozide.
ElafinThe serum concentration of Pimozide can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pimozide.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Pimozide.
EliglustatPimozide may increase the QTc-prolonging activities of Eliglustat.
EnalaprilThe serum concentration of Pimozide can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Pimozide can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Pimozide can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pimozide.
EntacaponeThe risk or severity of adverse effects can be increased when Pimozide is combined with Entacapone.
EnzalutamideThe serum concentration of Pimozide can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Pimozide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pimozide.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pimozide.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pimozide.
EribulinEribulin may increase the QTc-prolonging activities of Pimozide.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Pimozide.
ErythromycinThe serum concentration of Pimozide can be increased when it is combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pimozide.
EscitalopramPimozide may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Pimozide can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Pimozide is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Pimozide.
EstriolThe serum concentration of Estriol can be increased when it is combined with Pimozide.
EstroneThe serum concentration of Estrone can be increased when it is combined with Pimozide.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pimozide.
EthanolPimozide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pimozide.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pimozide.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Pimozide.
EthosuximideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Pimozide is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Pimozide is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pimozide.
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Pimozide.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Pimozide.
EtorphineThe risk or severity of adverse effects can be increased when Pimozide is combined with Etorphine.
EtravirineThe serum concentration of Pimozide can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Pimozide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Pimozide.
EzogabineThe risk or severity of adverse effects can be increased when Pimozide is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Pimozide.
FelbamateThe risk or severity of adverse effects can be increased when Pimozide is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Fenfluramine is combined with Pimozide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pimozide.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pimozide.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Pimozide.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pimozide.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Pimozide.
FingolimodFingolimod may increase the QTc-prolonging activities of Pimozide.
FlecainideFlecainide may increase the QTc-prolonging activities of Pimozide.
FlibanserinThe risk or severity of adverse effects can be increased when Pimozide is combined with Flibanserin.
FluconazoleFluconazole may increase the arrhythmogenic activities of Pimozide.
FlucytosineFlucytosine may increase the arrhythmogenic activities of Pimozide.
FludiazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Pimozide.
FluoxetinePimozide may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Pimozide.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pimozide.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pimozide.
FluspirileneThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Pimozide.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone Propionate.
FluvoxamineThe serum concentration of Pimozide can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Pimozide.
FosamprenavirThe serum concentration of Pimozide can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pimozide can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Pimozide.
FosinoprilThe serum concentration of Pimozide can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Pimozide is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Pimozide is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Pimozide.
Fusidic AcidThe serum concentration of Pimozide can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pimozide.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Pimozide is combined with gabapentin enacarbil.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Pimozide.
GalantamineGalantamine may increase the QTc-prolonging activities of Pimozide.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Pimozide is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Pimozide.
GeldanamycinThe serum concentration of Pimozide can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Pimozide.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Pimozide.
GlutethimideThe risk or severity of adverse effects can be increased when Pimozide is combined with Glutethimide.
Glycerol PhenylbutyrateThe serum concentration of Pimozide can be increased when it is combined with Glycerol Phenylbutyrate.
GlyphosateGlyphosate may increase the arrhythmogenic activities of Pimozide.
GM6001The serum concentration of Pimozide can be increased when it is combined with GM6001.
GoserelinGoserelin may increase the QTc-prolonging activities of Pimozide.
GranisetronGranisetron may increase the QTc-prolonging activities of Pimozide.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Pimozide.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Pimozide.
GriseofulvinGriseofulvin may increase the arrhythmogenic activities of Pimozide.
GuanfacineThe risk or severity of adverse effects can be increased when Pimozide is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pimozide.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Pimozide.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Pimozide.
HaloproginHaloprogin may increase the arrhythmogenic activities of Pimozide.
HalothaneThe risk or severity of adverse effects can be increased when Pimozide is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Pimozide is combined with Heroin.
HexetidineHexetidine may increase the arrhythmogenic activities of Pimozide.
HexobarbitalThe risk or severity of adverse effects can be increased when Pimozide is combined with Hexobarbital.
HirulogThe serum concentration of Pimozide can be increased when it is combined with Hirulog.
HistrelinHistrelin may increase the QTc-prolonging activities of Pimozide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pimozide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Pimozide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pimozide.
Hydroxyamphetamine hydrobromidePimozide may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
HydroxyzineThe risk or severity of adverse effects can be increased when Pimozide is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Pimozide.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Pimozide.
IbutilideIbutilide may increase the QTc-prolonging activities of Pimozide.
IdelalisibThe serum concentration of Pimozide can be increased when it is combined with Idelalisib.
IloperidoneThe serum concentration of Pimozide can be increased when it is combined with Iloperidone.
IloperidonePimozide may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Pimozide can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Pimozide.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Pimozide.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Pimozide.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pimozide.
IndalpineThe risk or severity of adverse effects can be increased when Indalpine is combined with Pimozide.
IndapamideIndapamide may increase the QTc-prolonging activities of Pimozide.
IndinavirThe serum concentration of Pimozide can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Pimozide.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Pimozide.
IsavuconazoniumThe serum concentration of Pimozide can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Pimozide.
IsoconazoleIsoconazole may increase the arrhythmogenic activities of Pimozide.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pimozide.
IsoflurophateThe serum concentration of Pimozide can be increased when it is combined with Isoflurophate.
IsoniazidThe serum concentration of Pimozide can be increased when it is combined with Isoniazid.
IsradipineThe serum concentration of Pimozide can be increased when it is combined with Isradipine.
ItraconazoleItraconazole may increase the arrhythmogenic activities of Pimozide.
IvabradineIvabradine may increase the QTc-prolonging activities of Pimozide.
IvacaftorThe serum concentration of Pimozide can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Pimozide.
IxazomibThe serum concentration of Pimozide can be increased when it is combined with Ixazomib.
KetamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Pimozide.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pimozide.
KetobemidoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketobemidone.
KetoconazoleKetoconazole may increase the arrhythmogenic activities of Pimozide.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Pimozide.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Pimozide.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Pimozide.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pimozide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Pimozide.
LapatinibThe serum concentration of Pimozide can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Pimozide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Pimozide.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Pimozide.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Pimozide.
LepirudinThe serum concentration of Pimozide can be increased when it is combined with Lepirudin.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pimozide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Pimozide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pimozide.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pimozide.
LevocabastineThe risk or severity of adverse effects can be increased when Pimozide is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Pimozide is combined with Levodopa.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Pimozide.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Pimozide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pimozide is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Pimozide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pimozide.
LidocaineThe metabolism of Pimozide can be decreased when combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Lidocaine.
LinagliptinThe serum concentration of Pimozide can be increased when it is combined with Linagliptin.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Pimozide.
LisdexamfetaminePimozide may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Pimozide can be increased when it is combined with Lisinopril.
LithiumLithium may increase the neurotoxic activities of Pimozide.
LithiumThe risk or severity of adverse effects can be increased when Pimozide is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Pimozide is combined with Lofentanil.
LomitapideThe serum concentration of Pimozide can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Pimozide.
LopinavirThe serum concentration of Pimozide can be increased when it is combined with Lopinavir.
LopinavirPimozide may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pimozide.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pimozide.
LosartanThe serum concentration of Losartan can be increased when it is combined with Pimozide.
LovastatinThe serum concentration of Pimozide can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pimozide.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Pimozide.
LuliconazoleThe serum concentration of Pimozide can be increased when it is combined with Luliconazole.
LumefantrinePimozide may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe serum concentration of Pimozide can be increased when it is combined with Lurasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Pimozide is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Pimozide.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pimozide.
MeclizineThe risk or severity of adverse effects can be increased when Pimozide is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Pimozide.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pimozide.
MelperoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Melperone.
MephenterminePimozide may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pimozide.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pimozide.
MequitazinePimozide may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pimozide.
MetaxaloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Metaxalone.
MethadoneMethadone may increase the QTc-prolonging activities of Pimozide.
MethadoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pimozide is combined with Methadyl Acetate.
MethamphetaminePimozide may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Pimozide is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Pimozide is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pimozide.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pimozide.
MethotrimeprazineThe serum concentration of Pimozide can be increased when it is combined with Methotrimeprazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pimozide.
MethsuximideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pimozide.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Pimozide.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimozide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pimozide.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pimozide.
MetyrosinePimozide may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Pimozide.
MevastatinMevastatin may increase the arrhythmogenic activities of Pimozide.
MexiletineThe metabolism of Pimozide can be decreased when combined with Mexiletine.
MicafunginMicafungin may increase the arrhythmogenic activities of Pimozide.
MiconazoleMiconazole may increase the arrhythmogenic activities of Pimozide.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Pimozide.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pimozide.
MifepristoneThe serum concentration of Pimozide can be increased when it is combined with Mifepristone.
MifepristonePimozide may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Pimozide.
MiltefosineMiltefosine may increase the arrhythmogenic activities of Pimozide.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Pimozide.
MirabegronMirabegron may increase the QTc-prolonging activities of Pimozide.
MirtazapinePimozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pimozide.
MitotaneThe serum concentration of Pimozide can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Pimozide.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pimozide.
ModafinilThe serum concentration of Pimozide can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Pimozide can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Molindone.
MonensinMonensin may increase the arrhythmogenic activities of Pimozide.
MorphineThe serum concentration of Morphine can be increased when it is combined with Pimozide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pimozide.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Pimozide.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pimozide.
MyxothiazolMyxothiazol may increase the arrhythmogenic activities of Pimozide.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Pimozide can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pimozide.
NabiloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Pimozide.
NafcillinThe serum concentration of Pimozide can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may increase the arrhythmogenic activities of Pimozide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pimozide.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Pimozide.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Pimozide.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pimozide.
NatamycinNatamycin may increase the arrhythmogenic activities of Pimozide.
NCX 4016The serum concentration of Pimozide can be increased when it is combined with NCX 4016.
NefazodoneThe serum concentration of Pimozide can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Pimozide can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Pimozide can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Pimozide can be increased when it is combined with Nevirapine.
NicardipineThe serum concentration of Pimozide can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Pimozide.
NilotinibThe serum concentration of Pimozide can be increased when it is combined with Nilotinib.
NilotinibPimozide may increase the QTc-prolonging activities of Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Pimozide.
NitrazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Pimozide is combined with Nitrous oxide.
NitroxolineNitroxoline may increase the arrhythmogenic activities of Pimozide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Pimozide.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pimozide.
NormethadoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pimozide.
NystatinNystatin may increase the arrhythmogenic activities of Pimozide.
OctreotideOctreotide may increase the QTc-prolonging activities of Pimozide.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Pimozide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pimozide.
OlaparibThe serum concentration of Pimozide can be increased when it is combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pimozide.
OlopatadineThe risk or severity of adverse effects can be increased when Pimozide is combined with Olopatadine.
OmapatrilatThe serum concentration of Pimozide can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Pimozide.
OndansetronOndansetron may increase the QTc-prolonging activities of Pimozide.
OndansetronThe risk or severity of adverse effects can be increased when Pimozide is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Pimozide is combined with Opium.
OrphenadrinePimozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pimozide.
OsanetantThe risk or severity of adverse effects can be increased when Pimozide is combined with Osanetant.
OsimertinibThe serum concentration of Pimozide can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Pimozide can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pimozide.
OxiconazoleOxiconazole may increase the arrhythmogenic activities of Pimozide.
OxprenololThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pimozide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pimozide.
OxymorphoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Oxymorphone.
OxytocinOxytocin may increase the QTc-prolonging activities of Pimozide.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Pimozide.
pafuramidinepafuramidine may increase the arrhythmogenic activities of Pimozide.
PalbociclibThe serum concentration of Pimozide can be increased when it is combined with Palbociclib.
PaliperidonePimozide may increase the QTc-prolonging activities of Paliperidone.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Pimozide.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Pimozide.
ParaldehydePimozide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Pimozide.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pimozide.
PasireotidePasireotide may increase the QTc-prolonging activities of Pimozide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Pimozide.
Peginterferon alfa-2bThe serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the arrhythmogenic activities of Pimozide.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pimozide.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pimozide.
PerampanelThe risk or severity of adverse effects can be increased when Pimozide is combined with Perampanel.
PerflutrenPerflutren may increase the QTc-prolonging activities of Pimozide.
PerindoprilThe serum concentration of Pimozide can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Pimozide is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pimozide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pimozide.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pimozide.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Pimozide.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pimozide.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pimozide is combined with Phenoxyethanol.
PhenterminePimozide may decrease the stimulatory activities of Phentermine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pimozide.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pimozide.
PhosphoramidonThe serum concentration of Pimozide can be increased when it is combined with Phosphoramidon.
PipamperoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Pimozide.
PizotifenThe risk or severity of adverse effects can be increased when Pimozide is combined with Pizotifen.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Pimozide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pimozide.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Pimozide.
PosaconazolePosaconazole may increase the arrhythmogenic activities of Pimozide.
PramipexolePimozide may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Pimozide.
PrazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Pimozide.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Pimozide.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Pimozide.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pimozide.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pimozide.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Pimozide.
PrimidoneThe risk or severity of adverse effects can be increased when Pimozide is combined with Primidone.
PrinomastatThe serum concentration of Pimozide can be increased when it is combined with Prinomastat.
ProcainamideProcainamide may increase the QTc-prolonging activities of Pimozide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pimozide.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pimozide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pimozide.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Pimozide.
PromazinePromazine may increase the QTc-prolonging activities of Pimozide.
PromazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pimozide.
PropafenonePropafenone may increase the QTc-prolonging activities of Pimozide.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pimozide.
PropofolThe serum concentration of Pimozide can be increased when it is combined with Propofol.
PropofolThe risk or severity of adverse effects can be increased when Pimozide is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Pimozide.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pimozide.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Pimozide.
PSD502The risk or severity of adverse effects can be increased when Pimozide is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Quazepam.
QuetiapinePimozide may increase the QTc-prolonging activities of Quetiapine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Pimozide.
QuinaprilThe serum concentration of Pimozide can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Pimozide can be increased when it is combined with Quinidine.
QuinidinePimozide may increase the QTc-prolonging activities of Quinidine.
QuinineQuinine may increase the QTc-prolonging activities of Pimozide.
QuinupristinThe serum concentration of Pimozide can be increased when it is combined with Quinupristin.
RadicicolRadicicol may increase the arrhythmogenic activities of Pimozide.
RamelteonThe risk or severity of adverse effects can be increased when Pimozide is combined with Ramelteon.
RamiprilThe serum concentration of Pimozide can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Pimozide.
RanolazineThe serum concentration of Pimozide can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Pimozide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pimozide.
RemikirenThe serum concentration of Pimozide can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pimozide.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Pimozide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pimozide.
RifabutinThe metabolism of Pimozide can be increased when combined with Rifabutin.
RifampicinThe metabolism of Pimozide can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Pimozide.
RifapentineThe metabolism of Pimozide can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pimozide.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Pimozide.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Pimozide.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pimozide.
RitonavirThe serum concentration of Pimozide can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Pimozide can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pimozide.
RolapitantThe serum concentration of Pimozide can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Pimozide.
RomifidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Romifidine.
RopinirolePimozide may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Pimozide can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pimozide.
RotigotinePimozide may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pimozide.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Pimozide is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Pimozide.
Salicylhydroxamic AcidSalicylhydroxamic Acid may increase the arrhythmogenic activities of Pimozide.
Salicylic acidSalicylic acid may increase the arrhythmogenic activities of Pimozide.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Pimozide.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Pimozide.
SaquinavirThe serum concentration of Pimozide can be increased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Pimozide can be increased when it is combined with Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pimozide.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Pimozide.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Pimozide.
SertaconazoleSertaconazole may increase the arrhythmogenic activities of Pimozide.
SertindoleThe risk or severity of adverse effects can be increased when Pimozide is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Pimozide.
SevofluraneThe risk or severity of adverse effects can be increased when Pimozide is combined with Sevoflurane.
SildenafilThe serum concentration of Pimozide can be increased when it is combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Pimozide.
SiltuximabThe serum concentration of Pimozide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pimozide can be increased when it is combined with Simeprevir.
SinefunginSinefungin may increase the arrhythmogenic activities of Pimozide.
SirolimusSirolimus may increase the arrhythmogenic activities of Pimozide.
SitagliptinThe serum concentration of Pimozide can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Pimozide is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Pimozide.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Pimozide.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Pimozide.
SorafenibSorafenib may increase the QTc-prolonging activities of Pimozide.
SotalolSotalol may increase the QTc-prolonging activities of Pimozide.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Pimozide.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Pimozide.
SpiraprilThe serum concentration of Pimozide can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Pimozide can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Pimozide can be increased when it is combined with Stiripentol.
StiripentolThe risk or severity of adverse effects can be increased when Pimozide is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.
SulconazoleSulconazole may increase the arrhythmogenic activities of Pimozide.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Pimozide.
SulfisoxazoleThe serum concentration of Pimozide can be increased when it is combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Pimozide.
SunitinibSunitinib may increase the QTc-prolonging activities of Pimozide.
SuvorexantThe risk or severity of adverse effects can be increased when Pimozide is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Pimozide.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Pimozide.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Pimozide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pimozide.
TasimelteonThe risk or severity of adverse effects can be increased when Pimozide is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Pimozide.
TavaboroleTavaborole may increase the arrhythmogenic activities of Pimozide.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pimozide.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pimozide.
TelaprevirThe serum concentration of Pimozide can be increased when it is combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Pimozide.
TelithromycinThe serum concentration of Pimozide can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pimozide.
TemocaprilThe serum concentration of Pimozide can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Pimozide.
TenofovirThe metabolism of Pimozide can be decreased when combined with Tenofovir.
TerbinafineTerbinafine may increase the arrhythmogenic activities of Pimozide.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pimozide.
TerconazoleTerconazole may increase the arrhythmogenic activities of Pimozide.
TeriflunomideThe serum concentration of Pimozide can be decreased when it is combined with Teriflunomide.
TetrabenazinePimozide may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetrodotoxin.
ThalidomidePimozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pimozide.
TheophyllineThe metabolism of Pimozide can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pimozide.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pimozide.
ThiorphanThe serum concentration of Pimozide can be increased when it is combined with Thiorphan.
ThiothixeneThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiothixene.
ThymolThymol may increase the arrhythmogenic activities of Pimozide.
TiagabineThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiagabine.
TicagrelorThe serum concentration of Pimozide can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Pimozide can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Pimozide.
TioconazoleTioconazole may increase the arrhythmogenic activities of Pimozide.
TipranavirThe serum concentration of Pimozide can be increased when it is combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Tizanidine.
TocilizumabThe serum concentration of Pimozide can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Pimozide is combined with Tolcapone.
TolnaftateTolnaftate may increase the arrhythmogenic activities of Pimozide.
TolterodineTolterodine may increase the QTc-prolonging activities of Pimozide.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Pimozide.
TopiramateThe risk or severity of adverse effects can be increased when Pimozide is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Pimozide.
ToremifeneToremifene may increase the QTc-prolonging activities of Pimozide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pimozide.
TrandolaprilThe serum concentration of Pimozide can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Pimozide is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pimozide.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Pimozide.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pimozide.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pimozide.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pimozide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pimozide.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pimozide.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Pimozide.
TrimetrexateTrimetrexate may increase the arrhythmogenic activities of Pimozide.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pimozide.
TriprolidineThe risk or severity of adverse effects can be increased when Pimozide is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pimozide.
UbenimexThe serum concentration of Pimozide can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Pimozide.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Pimozide.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pimozide.
VandetanibPimozide may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Pimozide.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Pimozide.
VemurafenibPimozide may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Pimozide can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Pimozide can be increased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Pimozide is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Pimozide.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pimozide.
VildagliptinThe serum concentration of Pimozide can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Pimozide.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Pimozide.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Pimozide.
VoriconazoleVoriconazole may increase the arrhythmogenic activities of Pimozide.
VorinostatVorinostat may increase the QTc-prolonging activities of Pimozide.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pimozide.
XimelagatranThe serum concentration of Pimozide can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Pimozide is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pimozide.
ZiconotideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Pimozide.
ZileutonThe serum concentration of Pimozide can be increased when it is combined with Zileuton.
ZimelidineThe risk or severity of adverse effects can be increased when Zimelidine is combined with Pimozide.
ZiprasidoneThe serum concentration of Pimozide can be increased when it is combined with Ziprasidone.
ZiprasidonePimozide may increase the QTc-prolonging activities of Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Pimozide is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pimozide.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pimozide.
ZonisamideThe risk or severity of adverse effects can be increased when Pimozide is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Pimozide is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Pimozide is combined with Zotepine.
ZuclopenthixolPimozide may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  3. Silva MR, Bernardi MM, Cruz-Casallas PE, Felicio LF: Pimozide injections into the Nucleus accumbens disrupt maternal behaviour in lactating rats. Pharmacol Toxicol. 2003 Jul;93(1):42-7. [PubMed:12828573 ]
  4. Muscat R, Sampson D, Willner P: Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry. 1990 Aug 1;28(3):223-30. [PubMed:2378927 ]
  5. Zarrindast MR, Heidari MR: On the mechanisms by which theophylline changes core body temperature in mice. Eur J Pharmacol. 1994 May 12;257(1-2):13-20. [PubMed:8082693 ]
  6. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  8. Murphy LL, Adrian BA, Kohli M: Inhibition of luteinizing hormone secretion by delta9-tetrahydrocannabinol in the ovariectomized rat: effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists. Steroids. 1999 Sep;64(9):664-71. [PubMed:10503726 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Freedman SB, Patel S, Marwood R, Emms F, Seabrook GR, Knowles MR, McAllister G: Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther. 1994 Jan;268(1):417-26. [PubMed:8301582 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Kang J, Wang L, Cai F, Rampe D: High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol. 2000 Mar 31;392(3):137-40. [PubMed:10762666 ]
  2. Osypenko VM, Degtiar VIe, Naid'onov VG, Shuba IaM: [Blockade of HERG K+ channels expressed in Xenopus oocytes by antipsychotic agents]. Fiziol Zh. 2001;47(1):17-25. [PubMed:11296551 ]
  3. Shuba YM, Degtiar VE, Osipenko VN, Naidenov VG, Woosley RL: Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem Pharmacol. 2001 Jul 1;62(1):41-9. [PubMed:11377395 ]
  4. Kang J, Chen XL, Rampe D: The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel. Biochem Biophys Res Commun. 2001 Aug 24;286(3):499-504. [PubMed:11511086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Papadopoulos V, Brown AS, Hall PF: Calcium-calmodulin-dependent phosphorylation of cytoskeletal proteins from adrenal cells. Mol Cell Endocrinol. 1990 Dec 3;74(2):109-23. [PubMed:1965307 ]
  2. Wang XB, Sato N, Greer MA, Greer SE, McAdams S: Role of extracellular calcium and calmodulin in prolactin secretion induced by hyposmolarity, thyrotropin-releasing hormone, and high K+ in GH4C1 cells. Acta Endocrinol (Copenh). 1990 Aug;123(2):218-24. [PubMed:2120879 ]
  3. Strobl JS, Kirkwood KL, Lantz TK, Lewine MA, Peterson VA, Worley JF 3rd: Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res. 1990 Sep 1;50(17):5399-405. [PubMed:2386945 ]
  4. Cimino M, Weiss B: Characteristics of the binding of phenoxybenzamine to calmodulin. Biochem Pharmacol. 1988 Jul 15;37(14):2739-45. [PubMed:3134891 ]
  5. Mody I, Baimbridge KG, Miller JJ: Blockade of tetanic- and calcium-induced long-term potentiation in the hippocampal slice preparation by neuroleptics. Neuropharmacology. 1984 Jun;23(6):625-31. [PubMed:6146939 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  2. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23